<DOC>
	<DOC>NCT02938858</DOC>
	<brief_summary>The registry aims to compare the two first-line available treatment approaches in non-high-risk APL patients aged ≤ 70 years - ATRA plus chemotherapy and ATRA plus ATO - in terms of practitioner's choice between the two options, clinical effectiveness and cost-effectiveness, long-term outcome, and short- and long-term toxic effects.</brief_summary>
	<brief_title>French Registry of First-line Treatment of Acute Promyelocytic Leukemia</brief_title>
	<detailed_description>- Collection of epidemiological data on non-high-risk APL patients aged ≤ 70 years: age and sex distribution, medical history, prognostic factors (time to treatment start, severity of coagulopathy at presentation, Performance status…). - Documentation of clinical and biologic effectiveness of the two first-line treatment approaches available for non-high-risk APL patients. - Documentation of Minimal Residual Disease (MRD). - Correlation of clinical outcomes with the chosen therapy. - Validation of published prognostic factors and identification of new prognostic factors</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Promyelocytic, Acute</mesh_term>
	<criteria>Newlydiagnosed APL (either de novo or therapyrelated) based on cytologic criteria and confirmed by the presence of the t(15;17) translocation and/or by the detection of the fusion transcript PML/RARα. Nonhighrisk APL (White Blood Count &lt; 10000/μl at presentation) Age ≤ 70 years Relapsed APL Newlydiagnosed Highrisk APL (White Blood Count &gt; 10000/μl at presentation) Age &gt; 70 years</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>